Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02490904
PHASE3

Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)

Sponsor: Central Hospital, Nancy, France

View on ClinicalTrials.gov

Summary

Assess the impact of eplerenone (initiated within 2 hours prior to patient departure to the operating room and administered for 4 days during the post-operative period) on graft function evaluated by the measurement of glomerular filtration rate at 3 months - variable strongly associated with long-term graft survival.

Official title: Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation : Effect on Graft Function at 3 Months.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

132

Start Date

2016-10-19

Completion Date

2031-08

Last Updated

2023-06-18

Healthy Volunteers

No

Interventions

DRUG

Eplerenone

Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours

DRUG

Placebo

Double-blinded Placebo administered for 4 days at 25mg every 12 hours

Locations (7)

CHRU Besançon

Besançon, France

CHU Brest

Brest, France

CHU Dijon- Hôpital Bocage Central

Dijon, France

CHRU de Nancy

Nancy, France

CHU Reims-Hôpital Maison Blanche

Reims, France

CHU Saint Etienne

Saint-Etienne, France

NHC -CHRU Strasbourg

Strasbourg, France